Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;27(7):1045.
doi: 10.1016/j.cmi.2021.05.019. Epub 2021 May 15.

'Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness' - Author's reply

Affiliations
Comment

'Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness' - Author's reply

Martin Wolkewitz et al. Clin Microbiol Infect. 2021 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Guaraldi G., Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M., et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–e484. - PMC - PubMed
    1. Martinuka O., Cube M von, Wolkewitz M. Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness. Clin Microbiol Infect. 2021;27:949–957. - PMC - PubMed
    1. Renoux C., Azoulay L., Suissa S. Biases in evaluating the safety and effectiveness of drugs for COVID-19: designing real-world evidence studies. Am J Epidemiol. 2021 doi: 10.1093/aje/kwab028. - DOI - PMC - PubMed
    1. Austin P.C., Fine J.P. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. Stat Med. 2017;36:1203–1209. doi: 10.1002/sim.7215. - DOI - PMC - PubMed
    1. Latouche A., Allignol A., Beyersmann J., Labopin M., Fine J.P. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66:648–653. - PubMed

Substances